Search Results - "Kováčech, Branislav"

Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans by Weisová, Petronela, Cehlár, Ondrej, Škrabana, Rostislav, Žilková, Monika, Filipčík, Peter, Kováčech, Branislav, Prčina, Michal, Wojčiaková, Ľubica, Fialová, Ľubica, Smolek, Tomáš, Kontseková, Eva, Žilka, Norbert, Novák, Michal

“…Pathologically altered tau protein is a common denominator of neurodegenerative disorders including Alzheimer's disease (AD) and other tauopathies. Therefore,…”
Get full text

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study by Kruse, Niels, Persson, Staffan, Alcolea, Daniel, Bahl, Justyna M.C, Baldeiras, Ines, Capello, Elisabetta, Chiasserini, Davide, Bocchio Chiavetto, Luisella, Emersic, Andreja, Engelborghs, Sebastiaan, Eren, Erden, Fladby, Tormod, Frisoni, Giovanni, García-Ayllón, María-Salud, Genc, Sermin, Gkatzima, Olymbia, Heegaard, Niels H.H, Janeiro, André M, Kováčech, Branislav, Kuiperij, H. Bea, Leitão, Maria J, Lleó, Alberto, Martins, Madalena, Matos, Mafalda, Mollergard, Hanne M, Nobili, Flavio, Öhrfelt, Annika, Parnetti, Lucilla, de Oliveira, Catarina Resende, Rot, Uros, Sáez-Valero, Javier, Struyfs, Hanne, Tanassi, Julia T, Taylor, Peggy, Tsolaki, Magda, Vanmechelen, Eugeen, Verbeek, Marcel M, Zilka, Norbert, Blennow, Kaj, Zetterberg, Henrik, Mollenhauer, Brit

“…Abstract Decreased levels of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) in Parkinson's disease and related synucleinopathies have been reported,…”
Get full text

First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model by Kontsekova, Eva, Zilka, Norbert, Kovacech, Branislav, Novak, Petr, Novak, Michal

“…We have identified structural determinants on tau protein that are essential for pathological tau-tau interaction in Alzheimer's disease (AD). These regulatory…”
Get full text

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial by Novak, Petr, Dr, Schmidt, Reinhold, Prof, Kontsekova, Eva, Prof, Zilka, Norbert, PhD, Kovacech, Branislav, PhD, Skrabana, Rostislav, PhD, Vince-Kazmerova, Zuzana, PhD, Katina, Stanislav, PhD, Fialova, Lubica, PhD, Prcina, Michal, PhD, Parrak, Vojtech, MD, Dal-Bianco, Peter, MD, Brunner, Martin, MD, Staffen, Wolfgang, MD, Rainer, Michael, MD, Ondrus, Matej, MD, Ropele, Stefan, Ing, Smisek, Miroslav, MD, Sivak, Roman, Ing, Winblad, Bengt, Prof, Novak, Michal, Prof

“…Summary Background Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease…”
Get full text

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias by Hanes, Jozef, Kovac, Andrej, Kvartsberg, Hlin, Kontsekova, Eva, Fialova, Lubica, Katina, Stanislav, Kovacech, Branislav, Stevens, Eva, Hort, Jakub, Vyhnalek, Martin, Boonkamp, Lynn, Novak, Michal, Zetterberg, Henrik, Hansson, Oskar, Scheltens, Philip, Blennow, Kaj, Teunissen, Charlotte E., Zilka, Norbert

“…OBJECTIVETo investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with…”
Get full text

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease by Novak, Petr, Schmidt, Reinhold, Kontsekova, Eva, Kovacech, Branislav, Smolek, Tomas, Katina, Stanislav, Fialova, Lubica, Prcina, Michal, Parrak, Vojtech, Dal-Bianco, Peter, Brunner, Martin, Staffen, Wolfgang, Rainer, Michael, Ondrus, Matej, Ropele, Stefan, Smisek, Miroslav, Sivak, Roman, Zilka, Norbert, Winblad, Bengt, Novak, Michal

“…Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer's…”
Get full text

Profiling of Amino Acids in Urine Samples of Patients Suffering from Inflammatory Bowel Disease by Capillary Electrophoresis-Mass Spectrometry by Piestansky, Juraj, Olesova, Dominika, Galba, Jaroslav, Marakova, Katarina, Parrak, Vojtech, Secnik, Peter, Secnik, Jr, Peter, Kovacech, Branislav, Kovac, Andrej, Zelinkova, Zuzana, Mikus, Peter

“…Urine represents a convenient biofluid for metabolomic studies due to its noninvasive collection and richness in metabolites. Here, amino acids are valuable…”
Get full text

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 by Kovacech, Branislav, Cullen, Nicholas C., Novak, Petr, Hanes, Jozef, Kontsekova, Eva, Katina, Stanislav, Parrak, Vojtech, Fresser, Michal, Vanbrabant, Jeroen, Feldman, Howard H., Winblad, Bengt, Stoops, Erik, Vanmechelen, Eugeen, Zilka, Norbert

“…Background The spread of tau pathology closely correlates with the disease course and cognitive decline in Alzheimer's disease (AD). Tau-targeting…”
Get full text

N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization by Paholikova, Kristina, Salingova, Barbara, Opattova, Alena, Skrabana, Rostislav, Majerova, Petra, Zilka, Norbert, Kovacech, Branislav, Zilkova, Monika, Barath, Peter, Novak, Michal

“…Tau protein is a member of microtubule-associated protein family. Under pathological conditions, tau undergoes multiple modifications that lead to the…”
Get more information

Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation by Zilkova, Monika, Nolle, Anna, Kovacech, Branislav, Kontsekova, Eva, Weisova, Petronela, Filipcik, Peter, Skrabana, Rostislav, Prcina, Michal, Hromadka, Tomas, Cehlar, Ondrej, Rolkova, Gabriela Paulikova, Maderova, Denisa, Novak, Michal, Zilka, Norbert, Hoozemans, Jeroen J M

“…Immunotherapies targeting pathological tau have recently emerged as a promising approach for treatment of neurodegenerative disorders. We have previously…”
Get full text

Determination of immunogenic proteins in biopharmaceuticals by UHPLC–MS amino acid analysis by Piestansky, Juraj, Galba, Jaroslav, Olesova, Dominika, Kovacech, Branislav, Kovac, Andrej

“…Nowadays, there is a growing interest in innovative and more efficient therapeutics—biopharmaceuticals, based on peptides or proteins. There are increased…”
Get full text

The Distance between N and C Termini of Tau and of FTDP-17 Mutants Is Modulated by Microtubule Interactions in Living Cells by Di Primio, Cristina, Quercioli, Valentina, Siano, Giacomo, Rovere, Matteo, Kovacech, Branislav, Novak, Michal, Cattaneo, Antonino

“…The microtubule (MT)-associated protein Tau is a natively unfolded protein, involved in a number of neurodegenerative disorders, collectively called…”
Get full text

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern by Kovacech, Branislav, Fialova, Lubica, Filipcik, Peter, Skrabana, Rostislav, Zilkova, Monika, Paulenka-Ivanovova, Natalia, Kovac, Andrej, Palova, Denisa, Rolkova, Gabriela Paulikova, Tomkova, Katarina, Csokova, Natalia Turic, Markova, Karina, Skrabanova, Michaela, Sinska, Kristina, Basheer, Neha, Majerova, Petra, Hanes, Jozef, Parrak, Vojtech, Prcina, Michal, Cehlar, Ondrej, Cente, Martin, Piestansky, Juraj, Fresser, Michal, Novak, Michal, Slavikova, Monika, Borsova, Kristina, Cabanova, Viktoria, Brejova, Bronislava, Vinař, Tomas, Nosek, Jozef, Klempa, Boris, Eyer, Ludek, Hönig, Vaclav, Palus, Martin, Ruzek, Daniel, Vyhlidalova, Tereza, Strakova, Petra, Mrazkova, Blanka, Zudova, Dagmar, Koubkova, Gizela, Novosadova, Vendula, Prochazka, Jan, Sedlacek, Radislav, Zilka, Norbert, Kontsekova, Eva

“…The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S…”
Get full text

Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease by Stozicka, Zuzana, Zilka, Norbert, Novak, Petr, Kovacech, Branislav, Bugos, Ondrej, Novak, Michal

“…Numerous epidemiological studies demonstrate that genetic background modifies the onset and the progression of Alzheimer's disease and related…”
Get full text

Transition of tau protein from disordered to misordered in Alzheimer's disease by Kovacech, Branislav, Skrabana, Rostislav, Novak, Michal

“…The neuronal protein tau, a member of the class of intrinsically disordered proteins, is characterized by the absence of any firm 3-D structure and high…”
Get more information

New Age of Neuroproteomics in Alzheimer's Disease Research by Kovacech, Branislav, Zilka, Norbert, Novak, Michal

“…Alzheimer's disease (AD) is the leading cause of dementia, a condition that gradually destroys brain cells and leads to progressive decline in mental…”
Get full text

Generation, accumulation and degradation of aberrant tau proteins in cortical neurons of transgenic rat during pathogenesis of chronic neurodegenerative disease by Filipcik, Peter, Krajciova, Gabriela, Cente, Martin, Skrabana, Rostislav, Kovacech, Branislav, Kontsekova, Eva, Novak, Michal

“…Increased accumulation of misfolded proteins in neurons of central nervous system is a typical feature of tauopathies including Alzheimer's disease (AD). Our…”
Get full text

Preparation, crystallization and preliminary X-ray analysis of the Fab fragment of monoclonal antibody MN423, revealing the structural aspects of Alzheimer's paired helical filaments by Csóková, Natália, Skrabana, Rostislav, Urbániková, L'ubica, Kovácech, Branislav, Popov, Alexander, Sevcík, Jozef, Novák, Michal

“…Monoclonal antibody (mAb) MN423 recognizes Alzheimer's disease specific conformation of tau protein assembled into paired helical filaments (PHF). Since the…”
Get more information

Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease by Kontsekova, Eva, Zilka, Norbert, Kovacech, Branislav, Skrabana, Rostislav, Novak, Michal

“…Pathologically modified tau protein is the main feature of Alzheimer's disease (AD) and related tauopathies. Therefore, immunotherapies that target…”
Get full text

A simple and rapid LC-MS/MS and CE-MS/MS analytical strategy for the determination of therapeutic peptides in modern immunotherapeutics and biopharmaceutics by Piestansky, Juraj, Barath, Peter, Majerova, Petra, Galba, Jaroslav, Mikus, Peter, Kovacech, Branislav, Kovac, Andrej

“…[Display omitted] •Modern and progressive UHPLC-MS/MS and CE-MS/MS analysis of peptide conjugates.•Fast non-enzymatic peptide cleavage.•Sensitive and selective…”
Get full text